AUTOLOGOUS BONE MARROW TRANSPLANTS--BREAST/OVARY CANCER

该计划项目赠款评估了剂量强化在 乳腺癌和卵巢癌的治疗。我们建议使用大剂量 烷化剂联合骨髓支持治疗急性髓系白血病 联合用药诱导化疗后早期转移性乳腺癌 阿霉素联合大剂量化疗和骨髓支持治疗 高危II期乳腺癌累及10个或以上淋巴结 全身剂量环磷酰胺和硫代替巴骨髓支持和治疗 进行大剂量治疗和自体移植的I期和II期试验 卵巢癌患者的骨髓支持。 使用多种单抗，我们将监测骨髓中的 与恶性乳腺癌细胞的侵袭和发展 去除恶性污染的免疫药理方法。 两个项目将尝试改善高剂量的毒性 化疗。我们将使用重组技术扩展我们的初步观察 粒细胞巨噬细胞集落刺激因子(rHuGM-CSF)在缩短过程中的作用 大剂量治疗和自体骨髓移植后的骨髓抑制期 通过进行随机对照试验进行骨髓支持。我们会 进行调查以了解耐火材料的机理 和功能性血小板减少症，并评估治疗方法。 这些项目的绩效得到三个核心项目的支持， 涉及超低温保存、统计和管理。

This Program Project Grant evaluates the role of dose-intensification in the treatment of breast and ovarian cancer. We propose to use high dose combination alkylating agents and bone marrow support in the treatment of early metastatic breast cancer following induction chemotherapy with adriamycin and to use high dose chemotherapy and bone marrow support in high risk Stage II Breast cancer involving 10 or more lymph nodes and high dose systemic cyclophosphamide and thiotepa with bone marrow support and to perform phase I and phase II trials of high dose therapy and autologous bone marrow support in ovarian cancer. Using multiple monoclonal antibodies, we will monitor bone marrow for involvement with malignant breast cancer cells and develop immunopharmacologic methods for removing the malignant contamination. Two projects will attempt to ameliorate the toxicity of high dose chemotherapy. We will extend our initial observations using recombinant granulocyte macrophage colony-stimulating-factor (rHuGM-CSF) in shortening the period of myelosuppression following high dose therapy and autologous bone marrow support by performing a randomized, comparative trial. We will perform investigations to understand the mechanism underlying refractory and dysfunctional thrombocytopenia and evaluate the therapeutic approaches. The performance of these projects is supported by three core projects, involving cryopreservation, statistics and administration.